Olema Oncology Reports Second Quarter 2026 Financial and Operating Results
Olema Pharmaceuticals, Inc. (OLMA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Olema Oncology Reports Second Quarter 2026 Financial and Operating Results • Completed enrollment in the pivotal Phase 3 OPERA-01 trial; top-line data are now expected in the first quarter of 2027 • Presented initial Phase 1 clinical data for OP-3136 at the 2026 ASCO
How this was made
The 30-second read
Why it matters
Traders can update models for palazestrant’s pivotal OPERA-01 timeline (top-line now expected in Q1 2027) and for OP-3136’s expansion into mCRPC via a Bayer darolutamide combination supply agreement.
Market read
The filing provides a concrete execution milestone (OPERA-01 enrollment complete) and a revised readout window (Q1 2027), plus a new partnership that broadens OP-3136’s clinical footprint.
What to watch
Cash is sizable ($461.1M) but net loss and R&D/G&A increases continue, so dilution risk and burn-rate trajectory remain key to any sustained rerating.
Background
This is an SEC 8-K (Item 2.02) with Olema’s Q2 2026 financial and operating results, including updated Phase 3 timing and new OP-3136 collaboration details.
Ticker impact
Olema says OPERA-01 Phase 3 enrollment is complete and top-line data are now expected in Q1 2027, plus a Bayer darolutamide combo deal for OP-3136.
Moderate positive bias, with trading likely to focus on the updated Q1 2027 timeline and any subsequent trial-readout milestones.
The filing is a primary disclosure (8-K with operating results and updated trial expectations) and includes a new clinical collaboration, both of which can re-rate probability-weighted timelines and pipeline value.
Market effects
Reinforces investor focus on endocrine SERD/CERAN and KAT6 inhibitor pipelines, and on partnering activity to de-risk late-stage development.
Limited, company-specific biotech news with no clear regional macro linkage.
Primarily US-listed biotech-specific; Bayer partnership may draw international attention but no broader regulatory or market-wide signal is stated.
Counterpoint
The update mainly changes timing to Q1 2027 and adds early-stage combo work, which may not translate into near-term valuation without efficacy readouts.
Key entities
- companyOlema Pharmaceuticals, Inc.
Nasdaq-listed clinical-stage biopharmaceutical company reporting Q2 2026 results and pipeline updates.
- clinical_trialOPERA-01
Pivotal Phase 3 trial of palazestrant as monotherapy; enrollment completed and top-line expected in Q1 2027.
- drug_candidateOP-3136
KAT6 inhibitor with initial Phase 1 data; collaboration with Bayer to evaluate with darolutamide in mCRPC.
- companyBayer
Partner in a clinical trial collaboration and supply agreement for OP-3136 plus darolutamide in mCRPC.
